A C-suite executive at a small / medium women’s health pharma company has expertise in molecular biology / genetics, precision medicine, ovarian health & aging, fertility, and menopause. This stakeholder discusses precision medicine strategies for fertility and menopausal care. They consider investment, research, demonstrated clinical utility / validity, gold standard for testing, and limited access to care to be key challenges. They rate unmet needs highest in endometriosis and precision medicine activity in the next 1-2 years highest in menstrual health and fertility. They are excited by activity from Celmatix, Luca Biologics, Clue, Flow, Kindbody, Contraline, Gameto, Fertility, Inne, and WHOOP. They are also excited by companies working on menstrual blood biomarkers and smart tampons. This stakeholder discusses the current deployment of precision medicine strategies, unmet needs, complexity of disease, and future opportunity for precision medicine in menopausal care. In the future, they expect to see the most activity in fertility, menstrual health, and digital health spaces which bring technologies into the home and allow for daily monitoring to enable future research.
PDF deck with summarized feedback from stakeholders
Individual PDFs of call transcripts with stakeholders
This package includes both the PDF deck and transcripts, providing a comprehensive understanding of stakeholders' views. You will receive a summarized report in the form of a PDF deck, as well as the full transcript of the discussions.
Individual call transcript of a single stakeholder discussing their views. This option is ideal for those who are interested in a specific stakeholder's perspective and insights on the topic.